Processing in Whole Tumor Cells Antigens for Cancer Immunotherapy

Abstract

Abstract: Whole tumor cell（WTC）as tumor antigens is a very promising alternative in tumor immune protection and immunotherapy, which can theoretically eliminate some important limitations in vaccine development. Whole tumor cells express a whole array of tumor associated antigens（TAAs）, and simultaneously can induce CTLs and CD4⁺ T helper cell activation. In this paper, some recent proceedings and current preparing methods of whole tumor cell antigens were reviewed including some types of WTC antigens, DC cells loaded by WTC antigens, and modification and immune enhancement of WTC antigens.

Key words: Whole tumor cell antigen, Dendritic cell, Immunotherapy

Fang Li, Hu Wei. Processing in Whole Tumor Cells Antigens for Cancer Immunotherapy[J]. Biotechnology Bulletin, 2013, 0(8): 23-27.

References

[1] Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells：March 2004 update[J]. Cancer Immunology, Immunotherapy, 2005, 54（3）：187-207.
[2] Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines[J]. Seminars in Immunology, 2010, 22：132-143.
[3] Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine[J]. Nature Medicine, 2000, 6：435-442.
[4] Wang XY, Arnouk H, Chen X, et al. Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma[J]. Journal of Immunology, 2006, 177：1543-1551.
[5] Apetoh L, Ghiringhelli F, Tesniere A, et al. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J]. Nature Medicine, 2007, 13：1050-1059.
[6] Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells[J]. Nature, 2003, 425（6957）：516-521.
[7] 刘彬, 邢芸, 张秀华, 等.佐剂增强的肿瘤细胞裂解物疫苗抗小鼠H22肝癌作用[J].生物学杂志, 2012, 29（3）：34-38.
[8] 崔莹莹, 冯盼盼, 张翔宇, 等.冻融肿瘤细胞和肿瘤细胞培养上清对淋巴细胞活化能力的影响[J].肿瘤研究与临床, 2012, 24（5）：291-294.
[9] Lachenal G, Pernet-Gallay K, Chivet M, et al. Release of exosomes from differentiated neurons and its regulation by synaptic glutamate-rgic activity[J]. Journal of Molecular Neuroscience, 2011, 46（2）：409-418.
[10] Dai S, Wei D, Wu Z, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer[J]. Molecular Therapy, 2008, 16：782-790.
[11] Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells：the near future[J]. International Journal of Cancer, 2001, 94：459-473.
[12] Vopenkova K, Mollova K, Buresova I, et al. Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy[J]. Journal of Cellular and Molecular Medicine, 2012, 16（11）：2827-2837.
[13] Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells[J]. Trends in Immunology, 2001, 22：141-148.
[14] Baruah P, Propato A, Dumitriu IE, et al. The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the crosspresentation of self, viral, and tumor antigens[J]. Blood, 2006, 107：151-158.
[15] Benencia F, Courreges M, Coukos G. Whole tumor antigen vac-cination using dendritic cells：comparison of RNA electroporation and pulsing with UV-irradiated tumor cells[J]. Journal of Tran-slational Medicine, 2008, 6：21-27.
[16] Filaci G, Contini P, Fravega M, et al. Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and participating in the development of anti-inflammatory functional behavior of phagocytic macrophages[J]. Human Immunology, 2003, 64：9-20.
[17] Eager R, John N. GM-CSF gene-transduced tumor vaccines[J]. Molecular Therapy, 2005, 12：18-27.
[18] Weide B, Carralot JP, Reese A, et al. Results of the first Phase I/II clinical vaccination trial with direct injection of Mrna[J]. Journal of Immunotherapy, 2008, 31：180-188.
[19] Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells[J]. Nature Medicine, 1997, 3：558-561.
[20] Wei Y, Sticca RP, Holmes LM, et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses[J]. International Journal of Oncology, 2006, 28（3）：585.
[21] Imura K, Ueda Y, Hayashi T, et al. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electro fusion technique[J]. International Journal of Oncology, 2006, 29（3）：53.
[22] Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses[J]. Clinical Cancer Research, 2004, 10：4699-4708.
[23] Aly HA. Cancer therapy and vaccination[J]. Journal of Immuno-logical Methods, 2012, 382（1-2）：1-23.
[24] Allison MED, Fearon DT. Enhanced immunogenicity of aldehyde-bearing antigens：a possible link between innate and adaptive immunity[J]. European Journal of Immunology, 2000, 30：2881-2887.
[25] Callahan MK, Chaillot D, Jacquin C, et al. Differential acquisition of antigenic peptides by HSP70 and HSC70 under oxidative conditions[J]. The Journal of Biological Chemistry, 2002, 277：33604-33609.
[26] Chiang CL, Ledermann JA, Egla A, et al. Oxidation of ovarian epit-helial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor[J]. Clinical Cancer Research, 2008, 14：4898-4907.
[27] Anderson MM, Requena JR, Crowley JR, et al. The myeloperoxidase system of human phagocytes generates Nepsilon（carboxymethyl）lysine on proteins：a mechanism for producing advanced glycation end products at sites of inflammation[J]. The Journal of Clinical Investigation, 1999, 104：103-113.
[28] Zhou R, Huang WJ, Ma C, et al. HOCl oxidation-modified CT26 cell vaccine inhibits colon tumor growth in a mouse model[J]. Asianpacific Journal of Cancerprevention, 2012, 13（8）：4037-4043.
[29] Chen M, Masaki T, Sawamura T. Lox-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells：implica-tions in endothelia dysfunction and atherosclerosis[J]. Pharm-acology and Therepy, 2002, 95：89-100.
[30] Delneste Y, Magistrelli G, Gauchat JF, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation[J]. Immu-nity, 2002, 17：353-362.
[31] Schirrmacher V, Ahlert T, Pr?stle T, et al. Immunization with virus-modified tumor cells[J]. Seminars in Oncology, 1998, 25：677-696.
[32] Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection：improvement of patient survival based on improved antitumor immune memory[J]. Cancer Immunology, Immunotherapy, 2005, 54：587-598.
[33] Drake CG. Prostate cancer as a model for tumor immunotherapy[J]. Nature Reviews Immunology, 2010, 10：580-593.